Trials / Completed
CompletedNCT00412997
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LBH589 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-05-01
- First posted
- 2006-12-19
- Last updated
- 2012-11-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00412997. Inclusion in this directory is not an endorsement.